In pulmonary arterial hypertension

United Therapeutics Corporation announced the results of the FREEDOM – C trial of oral treprostinil a retard formulation treprostinil, in pulmonary arterial hypertension . A preliminary analysis indicates that the study did not reach statistical significance for the primary endpoint, 6-minute walk distance at Week 16 .

‘While we are disappointed that we have a statistically significant result for the primary endpoint was not reached, we believe the results support the continued development of oral treprostinil, especially when the effect of treatment on the basis of of the dose in the FREEDOM-C trial is reached evaluated ‘said Roger Jeffs, United Therapeutics, President and Chief Operating Officer. ‘We remain excited for the prospects of of our Phase 3 trial of oral treprostinil, FREEDOM – M, study evaluates benefits of oral treprostinil without the presence of background therapy. This study is fully enrolled, and the results are expected at the end of 2009, available March. Furthermore, we expect enrollment of our Phase 3 trial of oral treprostinil, FREEDOM – DR, soon begin the the 0.25 mg tablet dose for patients. Finally put our inhaled treprostinil study, a statistically highly significant results and is the year of the FDA with an anticipated action date in April 2009. Submission in Europe via the centralized procedure is expected in January 2009. Jeff’s conclusion: ‘Today’s result is not the fact that we believe in in place today all the pieces that we need grow continue to grow our business is changing. ‘.

Courtesy of They can entire Kaiser Daily Health Policy is Reports view, by looking at archives or sign up for mail with an in Imperial Daily Health Policy Report strongly committed imperial network. A free service from the Henry J. Publishes. Kaiser Family Foundation.

click to follow